Aleglitazar

Revision as of 20:51, 8 August 2012 by WikiBot (talk | contribs) (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Template:Chembox new

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Aleglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by Hoffmann–La Roche for the treatment of type II diabetes. It is currently in phase II clinical trials.[1]

References

  1. ↑ ClinicalTrials.gov. "A Study of Aleglitazar in Patients With Type 2 Diabetes". United States National Institutes of Health. Retrieved 2008-03-19.

Template:Pharma-stub Template:Oral hypoglycemics

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Aleglitazar&oldid=668034"